Revenue

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

The cybersecurity firm will provide quantum-resistant tech for a massive MDA program, aiming to secure critical U.S. systems against future cyber threats.

New research shows assessment fraud more than doubled in 2025, driven by AI and hitting entry-level roles hardest. How can companies ensure fair hiring?

As AI adoption stalls at the pilot stage, new labs in Singapore, Japan, and the UK offer a crucial sandbox for testing high-stakes hybrid cloud deployments.

Legal tech firm DISCO reports strong growth fueled by a 600% surge in AI revenue, launching agentic AI and a disruptive new all-in-one pricing model.

With a key gene therapy approval imminent and major clinical data on deck, REGENXBIO's upcoming financial report will be a crucial test for the biotech.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

As Aura presents its precision oncology pipeline at key conferences, investors will weigh the promise of its lead drug against a challenging financial landscape.

While many cannabis firms struggle, Greenway Greenhouse reports a 40% revenue jump, expanding margins, and its fifth straight quarter of positive EBITDA.

As Kimco Realty prepares to present at the Raymond James conference, investors are watching for insights into its grocery-anchored retail strategy.

With its fifth straight EcoVadis Platinum rating and deep data transparency, ENNOVI is building a new blueprint for accountability in the industrial sector.

Investment firm Humanoid Global unveils a bold 2026 strategy: acquire a core robotics business and tap into China's market and defense applications.

With its new HAE drug EKTERLY® smashing revenue forecasts, KalVista heads to key conferences where investors will scrutinize its path to profitability.

Plus Therapeutics' REYOBIQ gains a crucial CPT code, a vital step in bringing this targeted radiotherapy to patients with aggressive brain cancers.

Landmark rulings in Canada & the U.S. sanction regulators for misconduct in the MyForexFunds case, raising serious questions about accountability.

A novel nasal spray for progressive MS shows it can calm brain inflammation and boost neuroprotection, offering new hope for a difficult-to-treat disease.

U.S. Energy Corp. unveils an ambitious plan to merge helium, oil, and carbon capture, but can this small-cap company deliver on its big promises?

Avista posts strong utility earnings but faces hurdles from investment losses and a key customer departure, unveiling a multi-billion dollar grid plan.

Rise Wellness launches its new 30g carbonated protein drink at Costco, betting on fizz and function to capture a rapidly growing, competitive market.

With its stock lagging, TScan Therapeutics will use a key conference to highlight upcoming clinical trial data and convince investors of its pipeline's value.